
    
      This is a non-inferiority study to examine Trastuzumab combined with chemotherapy or
      endocrine therapy in patients with metastatic Luminal B2 breast cancer subtype. The main
      purposes of this study are to test the safety and clinical benefit of Trastuzumab combined
      with chemotherapy or endocrine therapy in treating Luminal B2 breast cancer (hormone receptor
      positive and human epidermal growth factor receptor (HER2) positive or amplification). This
      multicentre, randomized study is designed to recruit up to 392 subjects to identify 196
      research subjects for each study treatment.
    
  